Sartorius to add flagship site in North America
The company plans to open a new 130,000-sq. ft plant in Ann Arbor in late 2023
German laboratory and pharmaceutical equipment provider, Sartorius, has announced plans to expand its presence in Michigan by opening a new 130,000-sq. ft (12,000-m2) state-of-the art plant in the Tech Loop, at the Ann Arbor Research Park in late 2023.
The moves comes as demand for innovative technologies used in developing and producing biopharmaceuticals continues to grow rapidly.
The new plant will focus on providing innovative solutions to help customers develop drugs that cure, prevent, and halt the progression of diseases.
The 15 acres of land the company has already purchased for its new flagship site will provide sufficient space for further expansion. By 2025, Sartorius anticipates it will more than double capacities for its key product groups.
Sartorius, which has 22 production sites worldwide, has said the new site is an integral part of its ongoing worldwide expansion, which will enable it to scale up its operations and capabilities in the Ann Arbor biotech hub. By 2025, Sartorius will more than double capacities for its key product groups.
The project is expected to create 160 jobs, including product development, operations, and other support functions, over 3 years.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
.png)
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
.png)
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
.png)
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
.png)
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance